September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- Healthcare CFOs prioritize cost control, data-driven decisions
- Study links intraoperative synthetic opioids, worse postoperative pain
- Tooth-in-eye surgery offers hope for restored vision
- Tenet Healthcare's strategic ASC expansion, hospital divestitures boost 2024 Q4 results
- Study: Prophylactic antibiotics reduce SSIs in pediatric cholecystectomy
- Trump signs executive order to enforce hospital price transparency rules
- Providence Health strike ends with wage increases, staffing changes
- Robotic surgery transforms ORs as market expands
- Study: Wildfire smoke raises hospital borrowing, patient care costs
- Study: Hospital bed shortage looms as aging population drives demand
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement